Highlights NeuroBo Pharmaceuticals, Inc.

Equities

NRBO

US64132R4048

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-02 pm EDT			5-day change	1st Jan Change
3.73 ^USD	+1.36%		+20.32%	+0.90%

Apr. 17	Sector Update: Health Care Stocks Mixed Wednesday Afternoon	MT
Apr. 17	NeuroBo Begins Dosing in Phase 1 Study of Obesity Treatment; Shares Rise	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Mixed Wednesday Afternoon	Apr. 17	MT
NeuroBo Pharmaceuticals, Inc. Doses First Patient in Its Phase 1 Clinical Trial Evaluating Da-1726 for the Treatment of Obesity	Apr. 17	CI
NeuroBo Pharmaceuticals, Inc. Completes Enrollment of Part 1 of Its Phase 2A Clinical Trial Evaluating DA-1241 for the Treatment of Mash	Apr. 01	CI
NeuroBo Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
NeuroBo Pharmaceuticals, Inc. Receives Safety Review Committee Approval to Continue with Its Phase 2A Clinical Trial Evaluating DA-1241 for the Treatment of Mash	Mar. 13	CI
NeuroBo Pharmaceuticals, Inc. Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity	Feb. 29	CI
NeuroBo Gets FDA Clearance For DA-1726 Trial in Obesity; Shares Soar	Feb. 01	MT
NeuroBo Shares Surge as Obesity Drug Moves to Phase I Trial	Feb. 01	DJ
NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment	Feb. 01	CI
Neurobo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of Da-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2A Clinical Trial Evaluating Da-1241 for the Treatment of Mash	Jan. 18	CI
NeuroBo Pharmaceuticals Regains Compliance With Nasdaq's Minimum Bid Price Rule	Jan. 09	MT
NeuroBo Pharmaceuticals Submits New Drug Application to FDA for Phase 1 Trial of DA-1726 for Obesity; Shares Rise	Dec. 28	MT
NeuroBo Pharmaceuticals Submits IND Application to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity	Dec. 28	CI
NeuroBo Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
NeuroBo Pharmaceuticals, Inc. Doses First Patient in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of Nash	23-09-15	CI
NeuroBo Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Neurobo Pharmaceuticals, Inc. Receives First Site IRB Approval for Its Phase 2A Clinical Trial Evaluating DA-1241 for the Treatment of NASH	23-08-03	CI
NeuroBo Pharmaceuticals Signs Agreement With MThera Pharma to Out-License Diabetic Neuropathy Treatment	23-08-02	MT
Neurobo Pharmaceuticals, Inc. Announces Da-1726 Effectively Reduces Body Weight and Glycemic Control Data At the American Diabetes Association's 83Rd Scientific Sessions	23-06-27	CI
NeuroBo Pharmaceuticals, Inc. Decides to Discontinue Its Clinical Development of ANA001 (Niclosamide) and Clinical Development of Gemcabene for the Treatment of COVID-19	23-06-02	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights NeuroBo Pharmaceuticals, Inc.

Equities

NRBO

US64132R4048

Highlights

Filters